Skip to content

BillionToOne, Inc. BLLN Offering costs in accounts payable and accrued expenses and other current liabilities

Offering costs in accounts payable and accrued expenses and other current liabilities at other companies

Immunome logo
ImmunomeIMNM
$0-100%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$106K
TRV
Trevi Therapeutics, Inc.TRVI
$58.25K
TRV
Trevi Therapeutics, Inc.TRVI
$58.25K
NetSTREIT logo
NetSTREITNTST
$502K+1,992%
Septerna, Inc. logo
Septerna, Inc.SEPN
$0-100%

Other financials

Income statement

See full
Revenue$108.4M+83.8%
Gross profit$79.1M+108%
Operating income$17.8M+870%
Net income$18.0M+551%
EPS (diluted)$0.34+187%

Balance sheet

See full
Cash & equivalents$537.5M+181%
Total debt$144.2M
Total equity$505.6M+300%
Total assets$700.7M

Cash flow

See full
Operating cash flow$15.4M+488%
CapEx$4.5M+90.5%
Free cash flow$11.0M+3,842%

Valuation

See full
Market cap$4.8B

Profitability

See full
Gross margin70.4%
Operating margin-96.9%
Net margin8.4%
FCF margin-83.4%

Returns & leverage

See full
Debt / equity0.3×
Current ratio10.9×

Where this comes from

Reported directly by BillionToOne, Inc. in its filing.

Tagged under the XBRL concept blln:OfferingCostIncludedInAccountsPayableAccruedExpensesAndOtherCurrentLiabilities.

The official record: BillionToOne, Inc. ’s 10-K, filed March 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about BillionToOne, Inc. 's offering costs in accounts payable and accrued expenses and other current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BillionToOne, Inc. 's offering costs in accounts payable and accrued expenses and other current liabilities?
BillionToOne, Inc. (BLLN) reported offering costs in accounts payable and accrued expenses and other current liabilities of $126K in Q4 2025.
What does offering costs in accounts payable and accrued expenses and other current liabilities mean?
Captures the portion of costs related to public or private securities offerings that have been accrued but not yet paid in cash. This metric highlights the impact of capital-raising activities on current liabilities and working capital. It helps investors understand the timing differences between incurring financing costs and the actual cash outflow.